Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Sutro Biopharma, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT05870748
- Locations
- 🇺🇸
Texas Oncology, Dallas, Texas, United States
🇺🇸Ohio State University Center, Columbus, Ohio, United States
🇺🇸Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida, United States
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 280
- Registration Number
- NCT05800587
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 509
- Registration Number
- NCT05740566
- Locations
- 🇧🇪
Vitaz campus Sint-Niklaas Moerland, Sint-Niklaas, Belgium
🇧🇷Beneficencia Portuguesa de Sao Paulo - Bp, Sao Paulo, São Paulo, Brazil
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 90
- Registration Number
- NCT05613088
- Locations
- 🇦🇺
Local Institution - 0016, Sydney, New South Wales, Australia
🇦🇺Local Institution - 0017, Waratah, New South Wales, Australia
🇦🇺Local Institution - 0015, Clayton, Victoria, Australia
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Conditions
- Interventions
- Procedure: Surgical resectionOther: Educational and Media InterventionOther: SOC, Educational and Media InterventionProcedure: Ommaya/VPSDrug: MethotrexateDrug: CisplatinDrug: VincristineDrug: CyclophosphamideDrug: CarboplatinDrug: TopotecanDrug: PegfilgrastimDrug: EtoposideDrug: FilgrastimRadiation: Irradiation
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05535166
- Locations
- 🇺🇸
Primary Children's Hospital, Salt Lake City, Utah, United States
🇺🇸Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States
🇺🇸Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT05521984
- Locations
- 🇺🇸
Washington University School of Medicine/St. Louis Children's Hospital, Saint Louis, Missouri, United States
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 231
- Registration Number
- NCT05429502
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸St Jude s Childrens Research Hospital, Memphis, Tennessee, United States
🇺🇸Cohen Children's Medical Center of New York, New Hyde Park, New York, United States
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 64
- Registration Number
- NCT05303727
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
- Conditions
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 6
- Registration Number
- NCT05246111
- Locations
- 🇭🇺
Magyar Honvédség Egészségügyi Központ, Podmaniczky utcai telephely, Onkológiai Osztály, Budapest, Hungary
🇭🇺PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 705
- Registration Number
- NCT05153239
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇱Clinical Research Chile SpA, Valdivia, Los Ríos, Chile
🇨🇭University Hospital Basel, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.